FORM 4

obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
---	--

**OMB APPROVAL** OMB Number:

Estimated average burden hours per response: 0.5

Filed numbers and to Cootion 10(a) of the Consulting Evaluation Act of 10
Filed pursuant to Section 16(a) of the Securities Exchange Act of 19
or Section 30(h) of the Investment Company Act of 1040

1. Name and Address of Reporting Person*  Mullennix Stephen						2. Issuer Name and Ticker or Trading Symbol UroGen Pharma Ltd. [ URGN ]									all appli Directo	icable)	ıg Per	rson(s) to Iss 10% O Other (s	wner
(Last) (First) (Middle) C/O UROGEN PHARMA LTD. 499 PARK AVENUE					3. Date of Earliest Transaction (Month/Day/Year) 11/14/2019									below		ating	below)		
(Street) NEW YOU CITY (City)	N		10022 (Zip)		4.1	If Amendment, Date of Original Filed (Month/Day/Year)  6. Indiv. Line)  X							ne)	lividual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person					
		Tab	le I - N	on-Deri	vative	e Sec	urit	ies Ac	quire	d, Di	sposed o	of, or Be	nefici	ally C	)wne	d			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/					Execution					es Acquired (A) or Of (D) (Instr. 3, 4 a		5)	5. Amor Securiti Benefic Owned Reporte	ies :ially Following	Forn (D) c	n: Direct or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) or (D)	Price	Transa (Instr. 3		tion(s)			(instr. 4)	
Ordinary Shares 11/14/					2019	019					1,759	A	(1)		8	,291		D	
Ordinary	Shares			11/14/	2019				S		608(2)	D	\$25.9	973	7	,683 D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Dee Execution if any (Month/I		4. Transa Code ( 8)				6. Date Expirati (Month/	on Da		7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		Deri Sec (Ins	Price of rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly G	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amoun or Numbe of Shares						
Restricted Stock	(1)	11/14/2019			M			1,759	(3)		(3)	Ordinary	1,759	\$	0.00	8,796		D	

## **Explanation of Responses:**

- 1. Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
- 2. Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
- 3. The reporting person was granted restricted stock units ("RSUs") on March 7, 2018, June 4, 2018 and October 28, 2018 representing 21,107 ordinary shares in the aggregate. 1/3rd of the RSUs vested on February 14, 2019, with the balance vesting in equal quarterly installments thereafter over a period of two years.

## Remarks:

/s/ Peter Pfreundschuh, Attorney-in-Fact

11/18/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.